Teng Moua1, Fabien Maldonado2, Paul A Decker3, Craig E Daniels2, Jay H Ryu2. 1. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. Electronic address: moua.teng@mayo.edu. 2. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To assess the frequency and clinical implications of positive autoimmune serologies in patients with biopsy-confirmed idiopathic pulmonary fibrosis (IPF). PATIENTS AND METHODS: We reviewed the records of patients at our institution with biopsy-confirmed usual interstitial pneumonia (UIP) from January 1, 1995, through December 31, 2010, for frequency and distribution of autoimmune serologies. Patients with IPF with and without positive serologies were compared. RESULTS: Three hundred eighty-nine consecutive patients with biopsy-confirmed IPF underwent serologic testing, with positive serologic test results being found in 112 (29%). Of 2051 individual screening serologic tests performed, results of 163 tests were positive (8%), with antinuclear antibody being the most frequent (47%). There was no difference in age at biopsy (P=.21), gender (P=.21), or presenting radiologic features between those with or without positive serology. More frequent use of immunosuppressive treatment (P=.02) was noted in those with positive serology. No survival difference was observed (log-rank; P=.43). Median follow-up for the whole cohort was 43.5 months. CONCLUSION: Positive autoimmune serology may occur in as much as one-third of the patients with biopsy-confirmed IPF with no associated clinical implication or survival advantage. Systematic use of autoimmune laboratory panels in patients without clinical features of connective tissue disease should be reconsidered in patients with suspected UIP on chest computed tomography scan or confirmed UIP on biopsy.
OBJECTIVE: To assess the frequency and clinical implications of positive autoimmune serologies in patients with biopsy-confirmed idiopathic pulmonary fibrosis (IPF). PATIENTS AND METHODS: We reviewed the records of patients at our institution with biopsy-confirmed usual interstitial pneumonia (UIP) from January 1, 1995, through December 31, 2010, for frequency and distribution of autoimmune serologies. Patients with IPF with and without positive serologies were compared. RESULTS: Three hundred eighty-nine consecutive patients with biopsy-confirmed IPF underwent serologic testing, with positive serologic test results being found in 112 (29%). Of 2051 individual screening serologic tests performed, results of 163 tests were positive (8%), with antinuclear antibody being the most frequent (47%). There was no difference in age at biopsy (P=.21), gender (P=.21), or presenting radiologic features between those with or without positive serology. More frequent use of immunosuppressive treatment (P=.02) was noted in those with positive serology. No survival difference was observed (log-rank; P=.43). Median follow-up for the whole cohort was 43.5 months. CONCLUSION: Positive autoimmune serology may occur in as much as one-third of the patients with biopsy-confirmed IPF with no associated clinical implication or survival advantage. Systematic use of autoimmune laboratory panels in patients without clinical features of connective tissue disease should be reconsidered in patients with suspected UIP on chest computed tomography scan or confirmed UIP on biopsy.
Authors: Philippe R Bauer; Sanjay Kalra; Thomas G Osborn; Jennifer St Sauver; Andrew C Hanson; Darrell R Schroeder; Jay H Ryu Journal: Respir Med Date: 2015-01-31 Impact factor: 3.415
Authors: Paraskevi Kirgou; Sotirios I Sinis; Ilias E Dimeas; Ilias C Papanikolaou; Konstantinos Tatsis; Athena Gogali; Konstantinos I Gourgoulianis; Dimitrios P Bogdanos; Zoe Daniil Journal: Front Med (Lausanne) Date: 2022-08-08
Authors: Tasha E Fingerlin; Weiming Zhang; Ivana V Yang; Hannah C Ainsworth; Pamela H Russell; Rachel Z Blumhagen; Marvin I Schwarz; Kevin K Brown; Mark P Steele; James E Loyd; Gregory P Cosgrove; David A Lynch; Steve Groshong; Harold R Collard; Paul J Wolters; Williamson Z Bradford; Karl Kossen; Scott D Seiwert; Roland M du Bois; Christine Kim Garcia; Megan S Devine; Gunnar Gudmundsson; Helgi J Isaksson; Naftali Kaminski; Yingze Zhang; Kevin F Gibson; Lisa H Lancaster; Toby M Maher; Philip L Molyneaux; Athol U Wells; Miriam F Moffatt; Moises Selman; Annie Pardo; Dong Soon Kim; James D Crapo; Barry J Make; Elizabeth A Regan; Dinesha S Walek; Jerry J Daniel; Yoichiro Kamatani; Diana Zelenika; Elissa Murphy; Keith Smith; David McKean; Brent S Pedersen; Janet Talbert; Julia Powers; Cheryl R Markin; Kenneth B Beckman; Mark Lathrop; Brian Freed; Carl D Langefeld; David A Schwartz Journal: BMC Genet Date: 2016-06-07 Impact factor: 2.797